<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38275951</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>21</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Antiviral Mechanisms of Saucerneol from <i>Saururus chinensis</i> against Enterovirus A71, Coxsackievirus A16, and Coxsackievirus B3: Role of Mitochondrial ROS and the STING/TKB-1/IRF3 Pathway.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">16</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16010016</ELocationID><Abstract><AbstractText>Enterovirus A71 (EV71), coxsackievirus A16 (CVA16), and coxsackievirus B3 (CVB3) are pathogenic members of the <i>Picornaviridae</i> family that cause a range of diseases, including severe central nervous system complications, myocarditis, and pancreatitis. Despite the considerable public health impact of these viruses, no approved antiviral treatments are currently available. In the present study, we confirmed the potential of saucerneol, a compound derived from <i>Saururus chinensis</i>, as an antiviral agent against EV71, CVA16, and CVB3. In the in vivo model, saucerneol effectively suppressed CVB3 replication in the pancreas and alleviated virus-induced pancreatitis. The antiviral activity of saucerneol is associated with increased mitochondrial ROS (mROS) production. In vitro inhibition of mROS generation diminishes the antiviral efficacy of saucerneol. Moreover, saucerneol treatment enhanced the phosphorylation of STING, TBK-1, and IRF3 in EV71- and CVA16-infected cells, indicating that its antiviral effects were mediated through the STING/TBK-1/IRF3 antiviral pathway, which was activated by increased mROS production. Saucerneol is a promising natural antiviral agent against EV71, CVA16, and CVB3 and has potential against virus-induced pancreatitis and myocarditis. Further studies are required to assess its safety and efficacy, which is essential for the development of effective antiviral strategies against these viruses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Jae-Hyoung</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kangwon Institute of Inclusive Technology, Kangwon National University, Chuncheon 24341, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mun</LastName><ForeName>Seo-Hyeon</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Heejung</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-5986-9024</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Yong Soo</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seong-Ryeol</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Division of Acute Viral Diseases, Centers for Emerging Virus Research, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju 28159, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Min-Young</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ham</LastName><ForeName>Youngwook</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Nucleic Acid Therapeutics Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju 28116, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomolecular Science, KRIBB School of Bioscience, Korea University of Science and Technology (KUST), Daejeon 34113, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Hwa-Jung</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Beauty Art, Youngsan University, 142 Bansong Beltway, Busan 48015, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baek</LastName><ForeName>Won-Jin</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Beauty Art, Youngsan University, 142 Bansong Beltway, Busan 48015, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Sungchan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7627-978X</Identifier><AffiliationInfo><Affiliation>Nucleic Acid Therapeutics Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju 28116, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomolecular Science, KRIBB School of Bioscience, Korea University of Science and Technology (KUST), Daejeon 34113, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Hyun-Jeong</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0002-3844-928X</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kangwon Institute of Inclusive Technology, Kangwon National University, Chuncheon 24341, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NRF-2022R1I1A1A01061239</GrantID><Agency>National Research Foundation of Korea</Agency><Country /></Grant><Grant><GrantID>HI23C0195</GrantID><Agency>Korea Health Industry Development Institute</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494232">IRF3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050838">Interferon Regulatory Factor-3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="Y">Pancreatitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032134" MajorTopicYN="Y">Saururaceae</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050838" MajorTopicYN="N">Interferon Regulatory Factor-3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">coxsackievirus A16</Keyword><Keyword MajorTopicYN="N">enterovirus A71</Keyword><Keyword MajorTopicYN="N">mitochondrial ROS</Keyword><Keyword MajorTopicYN="N">saucerneol</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>26</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38275951</ArticleId><ArticleId IdType="pmc">PMC10821076</ArticleId><ArticleId IdType="doi">10.3390/v16010016</ArticleId><ArticleId IdType="pii">v16010016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lu G., Qi J., Chen Z., Xu X., Gao F., Lin D., Qian W., Liu H., Jiang H., Yan J., et al. Enterovirus 71 and coxsackievirus A16 3C proteases: Binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J. Virol. 2011;85:10319–10331. doi: 10.1128/JVI.00787-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00787-11</ArticleId><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K.T., Chang H.L., Wang S.T., Cheng Y.T., Yang J.Y. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998–2005. Pediatrics. 2007;120:e244–e252. doi: 10.1542/peds.2006-3331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-3331</ArticleId><ArticleId IdType="pubmed">17671037</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairweather D., Stafford K.A., Sung Y.K. Update on coxsackievirus B3 myocarditis. Curr. Opin. Rheumatol. 2012;24:401–407. doi: 10.1097/BOR.0b013e328353372d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0b013e328353372d</ArticleId><ArticleId IdType="pmc">PMC4536812</ArticleId><ArticleId IdType="pubmed">22488075</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonen-Tikka M.L., Pflueger M., Klemola P., Savolainen-Kopra C., Smura T., Hummel S., Kaijalainen S., Nuutila K., Natri O., Roivainen M., et al. Human enterovirus infections in children at increased risk for type 1 diabetes: The Babydiet study. Diabetologia. 2011;54:2995–3002. doi: 10.1007/s00125-011-2305-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-011-2305-3</ArticleId><ArticleId IdType="pubmed">21932150</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q., Yan D., Song Y., Zhu S., He Y., Han Z., Wang D., Ji T., Zhang Y., Xu W. Whole-genome analysis of coxsackievirus B3 reflects its genetic diversity in China and worldwide. Virol. J. 2022;19:69. doi: 10.1186/s12985-022-01796-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01796-0</ArticleId><ArticleId IdType="pmc">PMC9014606</ArticleId><ArticleId IdType="pubmed">35436962</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G., Zhou F., Gu B., Ding C., Feng D., Xie F., Wang J., Zhang C., Cao Q., Deng Y., et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch. Virol. 2012;157:669–679. doi: 10.1007/s00705-011-1222-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1222-6</ArticleId><ArticleId IdType="pubmed">22245989</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevear D.C., Tull T.M., Seipel M.E., Groarke J.M. Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 1999;43:2109–2115. doi: 10.1128/AAC.43.9.2109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.43.9.2109</ArticleId><ArticleId IdType="pmc">PMC89431</ArticleId><ArticleId IdType="pubmed">10471549</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T.C., Weng K.F., Chang S.C., Lin J.Y., Huang P.N., Shih S.R. Development of antiviral agents for enteroviruses. J. Antimicrob. Chemother. 2008;62:1169–1173. doi: 10.1093/jac/dkn424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkn424</ArticleId><ArticleId IdType="pubmed">18931391</ArticleId></ArticleIdList></Reference><Reference><Citation>Shia K.S., Li W.T., Chang C.M., Hsu M.C., Chern J.H., Leong M.K., Tseng S.N., Lee C.C., Lee Y.C., Chen S.J., et al. Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: A novel class of potent and selective human enterovirus 71 inhibitors. J. Med. Chem. 2002;45:1644–1655. doi: 10.1021/jm010536a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm010536a</ArticleId><ArticleId IdType="pubmed">11931618</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotbart H.A. Antiviral therapy for enteroviruses and rhinoviruses. Antivir. Chem. Chemother. 2000;11:261–271. doi: 10.1177/095632020001100402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/095632020001100402</ArticleId><ArticleId IdType="pubmed">10950388</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Herrington D.T., Coats T.L., Kim K., Cooper E.C., Villano S.A., Liu S., Hudson S., Pevear D.C., Collett M., et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: Results of 2 double-blind, randomized, placebo-controlled trials. Clin. Infect. Dis. Off. Public Infect. Dis. Soc. Am. 2003;36:1523–1532. doi: 10.1086/375069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/375069</ArticleId><ArticleId IdType="pmc">PMC7199898</ArticleId><ArticleId IdType="pubmed">12802751</ArticleId></ArticleIdList></Reference><Reference><Citation>Anasir M.I., Zarif F., Poh C.L. Antivirals blocking entry of enteroviruses and therapeutic potential. J. Biomed. Sci. 2021;28:10. doi: 10.1186/s12929-021-00708-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-021-00708-8</ArticleId><ArticleId IdType="pmc">PMC7811253</ArticleId><ArticleId IdType="pubmed">33451326</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C.L., Yeo H., Ye H.Q., Liu S.Q., Shang B.D., Gong P., Alonso S., Shi P.Y., Zhang B. Inhibition of enterovirus 71 by adenosine analog NITD008. J. Virol. 2014;88:11915–11923. doi: 10.1128/JVI.01207-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01207-14</ArticleId><ArticleId IdType="pmc">PMC4178731</ArticleId><ArticleId IdType="pubmed">25100827</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung Y.W., Lee B.M., Ha M.T., Tran M.H., Kim J.A., Lee S., Lee J.H., Woo M.H., Min B.S. Lignans from Saururus chinensis exhibit anti-inflammatory activity by influencing the Nrf2/HO-1 activation pathway. Arch. Pharmacal Res. 2019;42:332–343. doi: 10.1007/s12272-018-1093-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-018-1093-4</ArticleId><ArticleId IdType="pubmed">30610615</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y., Yin Z., Jiang F., Xu J., Chen H., Gu Q. Two new lignans from the aerial parts of Saururus chinensis with cytotoxicity toward nasopharyngeal carcinoma. Fitoterapia. 2020;141:104344. doi: 10.1016/j.fitote.2019.104344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fitote.2019.104344</ArticleId><ArticleId IdType="pubmed">31465814</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Q., Lee J.W., Kim J.G., Lee D., Hong J.T., Kim Y., Lee M.K., Hwang B.Y. Lignans from Saururus chinensis with Inhibitory Effects on Nitric Oxide Production. J. Nat. Prod. 2019;82:3002–3009. doi: 10.1021/acs.jnatprod.9b00520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jnatprod.9b00520</ArticleId><ArticleId IdType="pubmed">31642320</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu S.Y., Oh K.S., Kim Y.S., Lee B.H. Antihypertensive, vasorelaxant and inotropic effects of an ethanolic extract of the roots of Saururus chinensis. J. Ethnopharmacol. 2008;118:284–289. doi: 10.1016/j.jep.2008.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2008.04.011</ArticleId><ArticleId IdType="pubmed">18495395</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D.H., Kim D.H., Oh I.Y., Kim S.Y., Lim Y.Y., Kim H.M., Kim Y.H., Choi Y.M., Kim S.E., Kim B.J., et al. Inhibitory effects of Saururi chinensis extracts on melanin biosynthesis in B16F10 melanoma cells. Biol. Pharm. Bull. 2013;36:772–779. doi: 10.1248/bpb.b12-00917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.b12-00917</ArticleId><ArticleId IdType="pubmed">23649335</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H.Y., Cho C.W., Song Y.S. Antioxidative and anti-inflammatory effects of Saururus chinensis methanol extract in RAW 264.7 macrophages. J. Med. Food. 2005;8:190–197. doi: 10.1089/jmf.2005.8.190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jmf.2005.8.190</ArticleId><ArticleId IdType="pubmed">16117611</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y.M., Xu Y.L., Zhang Z.L., Liu D.H., Cai M.T. Chemical Constituents from Saururus chinensis. Zhong Yao Cai = Zhongyaocai = J. Chin. Med. Mater. 2015;38:2538–2540.</Citation><ArticleIdList><ArticleId IdType="pubmed">27352534</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon S.H., Choi S.W., Park S.J., Ryu S.Y., Hwang K.S., Kim C.H., Kim S.H. In vitro and in vivo Bone-Forming Activity of Saururus chinensis Extract. Phytother. Res. PTR. 2015;29:1073–1080. doi: 10.1002/ptr.5349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.5349</ArticleId><ArticleId IdType="pubmed">25869918</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhen X., Choi H.S., Kim J.H., Kim S.L., Liu R., Yun B.S., Lee D.S. Machilin D, a Lignin Derived from Saururus chinensis, Suppresses Breast Cancer Stem Cells and Inhibits NF-κB Signaling. Biomolecules. 2020;10:245. doi: 10.3390/biom10020245.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10020245</ArticleId><ArticleId IdType="pmc">PMC7072518</ArticleId><ArticleId IdType="pubmed">32033472</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung S.H., Lee E.J., Cho J.H., Kim H.S., Kim Y.C. Sauchinone, a lignan from Saururus chinensis, attenuates CCl4-induced toxicity in primary cultures of rat hepatocytes. Biol. Pharm. Bull. 2000;23:666–668. doi: 10.1248/bpb.23.666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.23.666</ArticleId><ArticleId IdType="pubmed">10823687</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J.H., Ahn J.H., Kim S.R., Cho S., Hong E.H., Kwon B.E., Kim D.E., Choi M., Choi H.J., Cha Y., et al. Manassantin B shows antiviral activity against coxsackievirus B3 infection by activation of the STING/TBK-1/IRF3 signalling pathway. Sci. Rep. 2019;9:9413. doi: 10.1038/s41598-019-45868-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-45868-8</ArticleId><ArticleId IdType="pmc">PMC6599049</ArticleId><ArticleId IdType="pubmed">31253850</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz K.M., Neidermyer W.J., Tan Y.J., Whelan S.P.J., Kagan J.C. STING-dependent translation inhibition restricts RNA virus replication. Proc. Natl. Acad. Sci. USA. 2018;115:E2058–E2067. doi: 10.1073/pnas.1716937115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1716937115</ArticleId><ArticleId IdType="pmc">PMC5834695</ArticleId><ArticleId IdType="pubmed">29440426</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley J.S., Quarato G., Cloix C., Lopez J., O’Prey J., Pearson M., Chapman J., Sesaki H., Carlin L.M., Passos J.F., et al. Mitochondrial inner membrane permeabilisation enables mtDNA release during apoptosis. EMBO J. 2018;37:e99238. doi: 10.15252/embj.201899238.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201899238</ArticleId><ArticleId IdType="pmc">PMC6120664</ArticleId><ArticleId IdType="pubmed">30049712</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemball C.C., Alirezaei M., Flynn C.T., Wood M.R., Harkins S., Kiosses W.B., Whitton J.L. Coxsackievirus infection induces autophagy-like vesicles and megaphagosomes in pancreatic acinar cells in vivo. J. Virol. 2010;84:12110–12124. doi: 10.1128/JVI.01417-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01417-10</ArticleId><ArticleId IdType="pmc">PMC2976412</ArticleId><ArticleId IdType="pubmed">20861268</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevear D.C., Hayden F.G., Demenczuk T.M., Barone L.R., McKinlay M.A., Collett M.S. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob. Agents Chemother. 2005;49:4492–4499. doi: 10.1128/AAC.49.11.4492-4499.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.11.4492-4499.2005</ArticleId><ArticleId IdType="pmc">PMC1280128</ArticleId><ArticleId IdType="pubmed">16251287</ArticleId></ArticleIdList></Reference><Reference><Citation>Senior K. FDA panel rejects common cold treatment. Lancet Infect. Dis. 2002;2:264. doi: 10.1016/S1473-3099(02)00277-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(02)00277-3</ArticleId><ArticleId IdType="pubmed">12062983</ArticleId></ArticleIdList></Reference><Reference><Citation>Binford S.L., Maldonado F., Brothers M.A., Weady P.T., Zalman L.S., Meador J.W., 3rd, Matthews D.A., Patick A.K. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob. Agents Chemother. 2005;49:619–626. doi: 10.1128/AAC.49.2.619-626.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.2.619-626.2005</ArticleId><ArticleId IdType="pmc">PMC547258</ArticleId><ArticleId IdType="pubmed">15673742</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews D.A., Dragovich P.S., Webber S.E., Fuhrman S.A., Patick A.K., Zalman L.S., Hendrickson T.F., Love R.A., Prins T.J., Marakovits J.T., et al. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. USA. 1999;96:11000–11007. doi: 10.1073/pnas.96.20.11000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.20.11000</ArticleId><ArticleId IdType="pmc">PMC34232</ArticleId><ArticleId IdType="pubmed">10500114</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick A.K., Binford S.L., Brothers M.A., Jackson R.L., Ford C.E., Diem M.D., Maldonado F., Dragovich P.S., Zhou R., Prins T.J., et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 1999;43:2444–2450. doi: 10.1128/AAC.43.10.2444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.43.10.2444</ArticleId><ArticleId IdType="pmc">PMC89498</ArticleId><ArticleId IdType="pubmed">10508022</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Meijer A., Froeyen M., Zhang L., Thibaut H.J., Baggen J., George S., Vernachio J., van Kuppeveld F.J., Leyssen P., et al. Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68. Antimicrob. Agents Chemother. 2015;59:7782–7785. doi: 10.1128/AAC.01375-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01375-15</ArticleId><ArticleId IdType="pmc">PMC4649165</ArticleId><ArticleId IdType="pubmed">26369972</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schaar H.M., van der Linden L., Lanke K.H., Strating J.R., Pürstinger G., de Vries E., de Haan C.A., Neyts J., van Kuppeveld F.J. Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication. Cell Res. 2012;22:1576–1592. doi: 10.1038/cr.2012.129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2012.129</ArticleId><ArticleId IdType="pmc">PMC3494396</ArticleId><ArticleId IdType="pubmed">22945356</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillpotts R.J., Jones R.W., Delong D.C., Reed S.E., Wallace J., Tyrrell D.A. The activity of enviroxime against rhinovirus infection in man. Lancet. 1981;1:1342–1344. doi: 10.1016/S0140-6736(81)92520-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(81)92520-4</ArticleId><ArticleId IdType="pubmed">6113314</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourianfar H.R., Grollo L. Development of antiviral agents toward enterovirus 71 infection. J. Microbiol. Immunol. Infect. = Wei Mian Yu Gan Ran Za Zhi. 2015;48:1–8. doi: 10.1016/j.jmii.2013.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2013.11.011</ArticleId><ArticleId IdType="pubmed">24560700</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourianfar H.R., Poh C.L., Fecondo J., Grollo L. In vitro evaluation of the antiviral activity of heparan sulfate mimetic compounds against Enterovirus 71. Virus Res. 2012;169:22–29. doi: 10.1016/j.virusres.2012.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2012.06.025</ArticleId><ArticleId IdType="pubmed">22771616</ArticleId></ArticleIdList></Reference><Reference><Citation>Decout A., Katz J.D., Venkatraman S., Ablasser A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 2021;21:548–569. doi: 10.1038/s41577-021-00524-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00524-z</ArticleId><ArticleId IdType="pmc">PMC8029610</ArticleId><ArticleId IdType="pubmed">33833439</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoggins J.W. Interferon-Stimulated Genes: What Do They All Do? Annu. Rev. Virol. 2019;6:567–584. doi: 10.1146/annurev-virology-092818-015756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-092818-015756</ArticleId><ArticleId IdType="pubmed">31283436</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M., Wang Y., Li L., Liu S., Wang C., Yuan Y., Yang G., Chen Y., Cheng J., Lu Y., et al. Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance. Theranostics. 2021;11:1845–1863. doi: 10.7150/thno.50905.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.50905</ArticleId><ArticleId IdType="pmc">PMC7778599</ArticleId><ArticleId IdType="pubmed">33408785</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>